About Shenzhen Kangtai Biological Products Company

The company was founded in 1992 and listed on the Shenzhen Stock Exchange GEM in February 2017. It is the first listed vaccine company in South China. It has developed into a high-tech enterprise with complete R&D varieties, rich product lines, and obvious technical advantages. It has R&D and production capabilities for viral vaccines, bacterial vaccines, genetically engineered vaccines, conjugated vaccines, and multivalent multivalent vaccines. The company's main business is research and development, production and sales of human vaccines. Major products include recombinant hepatitis B vaccine (10ug, 20ug, 60ug), 23-valent pneumococcal polysaccharide vaccine, acellular haemophilus influenzae type b combination vaccine, 13-valent pneumococcal conjugate vaccine, and freeze-dried human rabies vaccine (human diploid cells). The company has received honors such as Guangdong Innovative Enterprise, Guangdong High-tech Product Certificate, National Torch Program Key High-tech Enterprise Certificate, Guangdong Youth Leading Enterprise, and Shenzhen Science and Technology Progress Award.